Publications de Nicolas Thomä

A Multicomponent Reaction-Based Platform Opens New Avenues in Aryl Hydrocarbon Receptor Modulation

A multidisciplinary platform is presented to address aryl hydrocarbon receptor (AhR) modulation. A rewired Yonemitsu multicomponent reaction with indole 2-carboxaldehydes and nucleophilic species was designed to access a family of 6-substituted indolocarba ...

American Chemical Society (ACS)2025

Primed for Degradation: How Weak Protein Interactions Enable Molecular Glue Degraders

Nicolas Thomä

Molecular glues are small drug-like molecules that induce de novo protein-protein interactions or facilitate pre-existing weak interactions between proteins. In the context of a ubiquitin ligase, such binding events frequently result in ubiquitination by p ...

CURRENT BIOLOGY LTD2025

Nucleosomes specify co-factor access to p53

Nicolas Thomä

Pioneer transcription factors (TFs) engage chromatinized DNA motifs. However, it is unclear how the resultant TF-nucleosome complexes are decoded by co-factors. In humans, the TF p53 regulates cell-cycle progression, apoptosis, and the DNA damage response, ...

2025

Niclosamide: CRL4AMBRA1 mediated degradation of cyclin D1 following mitochondrial membrane depolarization

Nicolas Thomä

Niclosamide, an FDA-approved anthelmintic drug, known to uncouple the mitochondria induces cyclin D1 degradation via CRL4 AMBRA1 . We find a striking correlation between the two processes and that it is observed amongst various compounds. ...

Royal Society of Chemistry (RSC)2025

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Nicolas Thomä

Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug discovery. So fa ...

Nature Research2024